Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone

Clinical and Experimental Ophthalmology

Volumn 37, Issue 6, 2009, Pages 602-608

  Mohamed, Shaheeda ^a,b   Leung, Gabriel M ^c   Chan, Carmen K M ^a,b   Lai, Timothy Y Y ^a,b   Lee, Vincent Y W ^a,d   Liu, David T L ^a,d   Li, Kenneth K W ^e   Li, Patrick S H ^f   Lam, Dennis S C ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e Queen May Hospital   (Hong Kong)

^f UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

Diabetic macular oedema; Retinal thickening; Triamcinolone acetonide; Visual acuity

Indexed keywords

TRIAMCINOLONE;

AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG RESPONSE; FEMALE; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; RISK REDUCTION; SURVIVAL; VISUAL ACUITY;

AGED; DIABETIC RETINOPATHY; FEMALE; FOVEA CENTRALIS; GLUCOCORTICOIDS; HUMANS; INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 68349144502     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2009.02104.x     Document Type: Article

References (23)

1. National Diabetes Data Group. Diabetes in America, 2nd edn. NIH Publication. No. 95-1468. US Govt.Printing Office:WAshington; 1995.
2. Ferris FL III, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984; 28(suppl): S452-61.
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-806.
4. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991; 98: 766-85.
5. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132: 425-7.
6. Martidis A, Duker JS, Greenberg PB et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-7.
7. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: An optical coherence tomography study. Br J Ophthalmol 2004; 88: 1131-6.
8. Karacorlu M, Ozdemir H, Karacorlu S, Alacali N, Mudun B, Burumcek E. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye 2005; 19: 382-6.
9. Lam DS, Chan CK, Tang EW, Li KK, Fan DS, Chan WM. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: Six-month prospective longitudinal pilot study. Clin Experiment Ophthalmol 2004; 32: 569-72.
10. Lam DS, Chan SK, Mohamed S et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: 6-month outcomes. Ophthalmol 2007; 114: 2162-7.
11. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmol 2003; 110: 681-6.
12. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004; 138: 158-60.
13. Chan CK, Mohamed S, Shanmugam MP, Tsang CW, Lai TY, Lam DS. Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema. Br J Ophthalmol 2006; 90: 1137-41.
14. Lam DS, Chan CK, Mohamed S et al. A prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular edema. Br J Ophthalmol 2007; 91: 199-203.
15. Diabetic Retinopathy Clinical Research Network. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol 2006; 124: 1701-7.
16. Chylack LT Jr, Wolfe JK, Singer DM et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 1993; 111: 831-6.
17. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114: 525-36.
18. Chan A, Duker JS. A standardized method for reporting changes in macular thickening using optical coherence tomography. Arch Ophthalmol 2005; 123: 939-43.
19. Diabetic Retinopathy Clinical Research Network. Reproducibility of macular thickness and volume using zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 2007; 114: 1520-5.
20. Jonas JB, Martus P, Degenring RF, Kreissig I, Akkoyun I. Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol 2005; 123: 1338-43.
21. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-59.
22. Shulman S, Ferencz JR, Gilady G, Ton Y, Assia E. Prognostic factors for visual acuity improvement after intravitreal triamcinolone injection. Eye 2007; 21: 1067-70.
23. Gibran SK, Khan K, Jungkim S, Cleary PE. Optical coherence tomographic pattern may predict visual outcome after intravitreal triamcinolone after diabetic macular edema. Ophthalmology 2007; 114: 890-4.